Objective:

To investigate how genetic differences influence the response to GLP-1-based weight-loss drugs and the risk of side effects.

Key Findings:

• Identification of a variant in the GLP1 receptor gene linked to greater weight loss (0.76 kg per variant copy).
• Genetic factors, along with clinical characteristics, accounted for about 25% of variability in treatment response.
• Variants near the GLP1 receptor gene were associated with nausea and vomiting, while a variant in the GIP receptor gene increased vomiting risk with tirzepatide.
• Patients with genetic variants linked to greater weight loss were more likely to experience gastrointestinal side effects.

Interpretation:

The study suggests that genetic factors play a role in both the efficacy and tolerability of GLP-1 therapies, indicating a shared biological mechanism.

Limitations:

• Genetic factors contributed only modestly to prediction accuracy for treatment response.
• Further research is needed to validate findings and improve predictive models.

Conclusion:

The findings support the potential for precision medicine in optimizing GLP-1 therapy, suggesting that genetic information could guide treatment decisions in the future.